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SUMMARY 
 
BACKGROUND AND PURPOSE 
The chemokine receptor CXCR3 directs the migration of T-cells in response to the ligands 
CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC.  Both ligands and receptor are implicated 
in the pathogenesis of inflammatory disorders including atherosclerosis and rheumatoid 
arthritis.  Here, we describe the molecular mechanism by which two synthetic small-molecule 
agonists activate CXCR3.  
 
EXPERIMENTAL APPROACH 
Since both small-molecules are basic, we hypothesized that they formed electrostatic 
interations with acidic residues within CXCR3.  Nine point mutants of CXCR3 were 
generated in which an acidic residue was mutated to its amide counterpart.   Following 
transient expression, the ability of the constructs to bind and signal in response to natural and 
synthetic ligands was examined. 
 
KEY RESULTS  
Although efficiently expressed and responsive to CXCL11 in chemotaxis assays, D112N, 
D195N and E196Q CXCR3 mutants showed a complete loss of responsiveness to CXCL10 
and to both synthetic agonists, which was confirmed with radioligand binding assays.  
Molecular modelling of both CXCL10 and CXCR3 suggests that the small-molecule agonists 
mimic a region of the 30’s loop which interacts with the intrahelical residue D112 leading to 
receptor activation.  D195 and E196 are located in the second extracellular loop and form 
putative intramolecular salt bridges required for a CXCR3 conformation that can recognize 
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CXCL10.  In contrast, CXCL11 recognition by CXCR3 is largely independent of these 
residues. 
 
CONCLUSIONS AND IMPLICATIONS 
We provide here a molecular basis for the observation that CXCL10 and CXCL11 are 
allosteric ligands of CXCR3. Such findings may have implications for the design of CXCR3 
antagonists.   
(248 words) 
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INTRODUCTION 
Chemokines are low molecular weight proteins that mediate the migration of leukocytes.  In 
the human, they constitute a family of over 40 proteins with the majority of chemokines 
falling into one of two groups, namely the CC or CXC classes, where the first two cysteine 
residues within the N-terminal region are either adjacent or have a single amino acid 
separating them (Zlotnik & Yoshie, 2000).  Chemokines exert their effects by binding to 
specific G protein-coupled receptors (GPCRs) expressed on the leukocyte surface (Murphy, 
2002; Murphy, Baggiolini, Charo, Hebert, Horuk, Matsushima et al., 2000).   The signals 
transduced by these receptors help to coordinate leukocyte trafficking and the establishment 
of lymphoid microenvironments.  Their discovery has greatly increased our understanding of 
selective leukocyte recruitment to sites of inflammation.  Indeed, the excessive or 
inappropriate release of chemokines has been linked with the pathogenesis of several 
inflammatory diseases and a variety of autoimmune disorders (Charo & Ransohoff, 2006).   
The chemokine receptor CXCR3 is expressed on the surface of a substantial proportion of 
freshly purified T-cells (Loetscher, Gerber, Loetscher, Jones, Piali, Clark-Lewis et al., 1996),  
is upregulated upon polarisation to the Th1 subset (Loetscher, Loetscher, Brass, Meese & 
Moser, 1998; Meiser, Mueller, Wise, McDonagh, Petit, Saran et al., 2008) and binds the 
chemokines CXCL9/Mig, CXCL10/IP-10 and CXCL11/I-TAC with nanomolar affinities 
(Cole, Strick, Paradis, Ogborne, Loetscher, Gladue et al., 1998; Weng, Siciliano, 
Waldburger, Sirotina-Meisher, Staruch, Daugherty et al., 1998).  All three CXCR3 ligands 
are induced by IFN-γ and therefore thought to promote Th1 immune responses (Cole, Strick, 
Paradis, Ogborne, Loetscher, Gladue et al., 1998; Farber, 1990; Luster & Ravetch, 1987), 
notably in the pathogenesis of several clinically important inflammatory disorders including 
rheumatoid arthritis and atherosclerosis (Kwak, Ha, Kim, Lee, Kim, Lee et al., 2008; 
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Tsubaki, Takegawa, Hanamoto, Arita, Kamogawa, Yamamoto et al., 2005). Since GPCRs are 
inherently “druggable” accounting for 40% of all prescribed drugs (Fredriksson, Lagerstrom, 
Lundin & Schioth, 2003), blockade of CXCR3 by small-molecules may suggest alternative 
therapeutic approaches to treat inflammation with several prototypic antagonists of CXCR3 
described in the literature (Pease & Horuk, 2009). Consequently much effort has been 
undertaken to understand the events underlying CXCR3 activation.  CXCL10 and CXCL11 
have distinct potencies and efficacies in a variety of assays including internalisation and cell 
migration (Colvin, Campanella, Manice & Luster, 2006; Colvin, Campanella, Sun & Luster, 
2004; Dagan-Berger, Feniger-Barish, Avniel, Wald, Galun, Grabovsky et al., 2006; Xanthou, 
Williams & Pease, 2003), suggesting that they interact with CXCR3 in different ways and 
likely stabilize different conformations of the receptor.  Previous work by ourselves and 
others has highlighted domains of CXCR3 implicated in ligand binding and receptor 
activation, notably the second extracellular loop (Colvin, Campanella, Manice & Luster, 
2006; Xanthou, Williams & Pease, 2003). In this study we use recently described small-
molecule agonists of CXCR3 to probe the structure-function relationships of ligands and 
receptor and identify key residues required for activation of CXCR3 by CXCL10 and small 
molecule mimetics of CXCL10.   
 
METHODS 
 
Materials - Reagents were purchased from Invitrogen (Paisley, UK), unless stated otherwise. 
Recombinant human CXCL10 and CXCL11 were purchased from PeproTech EC Ltd. 
(London, UK). The mouse anti-human CXCR3 mAb (clone 49801.111) and the mouse 
isotype-matched control IgG1 (MOPC 21 clone) were obtained from Sigma-Aldrich. The 
monoclonal mouse anti-haemagglutinin (HA) anti-HA.11 antibody was from Covance 
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(Berkeley, California) and its corresponding IgG1 isotype control antibody from Sigma-
Aldrich (Poole, UK). The murine pre-B cell line L1.2 was maintained as described previously 
(Vaidehi, Pease & Horuk, 2009) in suspension at 37°C with 5% CO2 at a density of no more 
than 1x106 cells/ml. The human lymphoma cell line H9 [Repository # 0001] was obtained 
from the Programme EVA Centre for AIDS Reagents, NIBSC, UK, supported by the EC 
FP6/7 Europrise Network of Excellence, AVIP and NGIN consortia and the Bill and Melinda 
Gates GHRC-CAVD Project and was donated by Dr R. Gallo, University of Maryland 
School of Medicine. H9 cells were maintained in suspension in RMPI medium supplemented 
with 10% FBS and 37°C with 5% CO2 at a density of no more than 1x106 cells/ml. 
 
Generation of receptor mutants and their transient expression in the murine pre-B cell line 
L1.2.  
Previously described pcDNA3 plasmids containing human wild type (WT) CXCR3 cDNA 
with an HA epitope tag encoded at the N terminus (Meiser, Mueller, Wise, McDonagh, Petit, 
Saran et al., 2008) were used as a template for the generation of point mutants by PCR using 
the QuikChange II site-directed mutagenesis kit (Stratagene, Amsterdam, Netherlands). All 
constructs were verified by DNA sequencing (Eurofins MWG Operon, Ebersberg, Germany) 
before use.  L1.2 cells were transiently transfected by electroporation with 1µg of vector 
DNA/106 cells at 330V, 975µF and incubated overnight in medium supplemented with 
10mM of sodium butyrate to enhance gene expression. 
 
Flow Cytometry.  Cell surface expression of CXCR3 was assessed by flow cytometry after 
staining with either mouse anti-human CXCR3 mAb or an anti-HA antibody and FITC-
conjugated secondary antibody as described previously (Vaidehi, Pease & Horuk, 2009).  
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Expression was analyzed using a FACSCalibur flow cytometer (Becton Dickinson, Mountain 
View, CA).  Data are presented as a percentage of the amount of WT CXCR3 expressed in 
control transfectants.  
 
Chemotaxis Assay. Assays of chemotactic responsiveness were carried out as previously 
described (Vaidehi, Pease & Horuk, 2009) using 96-well ChemoTx® plates with 5µm pores 
(Neuroprobe, Gaithersburg, MD).  Migrating cells were detected by the use of CellTiter 
Glo® Dye (Promega, Southampton, UK) and resulting luminescence measured using a 
TopCount scintillation counter (PerkinElmer, Waltham, MA).  Basal migration of cells to 
buffer alone was subtracted from the resulting data, with individual results expressed as a 
percentage of the total cells applied to the filter. In all experiments, each data point was 
assayed in duplicate. In every experiment, cells transiently expressing WT CXCR3 were 
employed as a positive control. 
 
Radiolabeled chemokine binding studies. Whole cell binding assays on transiently 
transfected L1.2 cells were performed as described previously (Vaidehi, Pease & Horuk, 
2009) using 0.1 nM 125I-CXCL10 or 125I-CXCL11 (Perkin Elmer) and increasing 
concentrations of unlabeled chemokine or antagonist.  Cell-associated radioactivity was 
counted in a Canberra Packard Cobra 5010 gamma counter (Canberra Packard, Pangebourne, 
UK).  Curve fitting and subsequent data analysis was carried out using the program PRISM 
(GraphPad Software, Inc., San Diego, CA) and IC50 values were obtained by nonlinear 
regression analysis.  In all experiments, each data point was assayed in duplicate.  
Background binding levels obtained in the presence of a 1000-3000 molar excess of 
unlabelled chemokine were subtracted from each data point and data are presented as the 
percentage of counts obtained in the absence of competing ligand.  Kd values were calculated 
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from homologous binding curves prepared in Graph Pad Prism (La Jolla, CA) using the 
equation  
 
where Bmax refers to the total ligand binding, [Hot] and [Cold] refer to the concentrations of 
labeled and unlabelled ligands respectively and NSB refers to non-specific binding.  
 
 
 
 
Three-dimensional alignments of CXCL10 with small-molecule CXCR3 agonists  
This was carried out using a novel multiple ligand alignment method as previously described 
(Anghelescu, DeLisle, Lowrie, Klon, Xie & Diller, 2008).  Visualization of the CXCL10 
crystal structure (Booth, Keizer, Kamphuis, Clark-Lewis & Sykes, 2002) was carried out 
using PyMol (DeLano, 2002) using structure 1LV9 from the Protein Data Bank 
(http://www.rcsb.org/pdb/home/home.do). 
 
Modelling CXCR3 interactions with small-molecule agonists 
The three dimensional model of the seven helical transmembrane bundle of human CXCR3 
was predicted using the ab initio method MembStruk (Vaidehi, Floriano, Trabanino, Hall, 
Freddolino, Choi et al., 2002; Vaidehi, Pease & Horuk, 2009). The extra and intracellular 
loops were added using the method, Modeller (Fiser, Do & Sali, 2000). In the extracellular 
loops 2 and 3 we observed that the residues D195 and R216 and E196 and K125 were in 
proximity and therefore performed constrained minimization to bring the pairs of residues 
together to form salt bridges. The small-molecules compounds 1 and 3 were built using the 
LigPrep module from the Schrodinger Glide suite (Schrodinger Inc). Multiple ligand 
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conformations were generated for the two compounds and docked using Glide XP 
(Schrodinger Inc). Next a short energy minimization was performed on each docked pose and 
the binding energy of this optimized pose was calculated. The binding energy was calculated 
as BE(binding energy)=PE(ligand in fixed protein) -PE(ligand in solvation); where BE is the 
binding energy and PE is the potential energy. The compound poses were then sorted by 
binding energy and the top 20 conformations inspected visually to maximize  the interactions 
with residues that are known to interact with ligands in chemokine receptors (Vaidehi, Pease 
& Horuk, 2009). 
 
Data and statistical analysis - Data are expressed as the mean ± SEM of at least three 
separate experiments, and were analysed with a relevant statistical test, where stated, using 
PRISM v4.03 software.  
 
Nomenclature 
Nomenclature of chemokine receptors within this manuscript the conforms to the BJP's 
Guide to Receptors and Channels (Alexander, Mathie & Peters, 2008). 
 
 
RESULTS 
 
Compounds #1 and #3 are partial agonists of CXCR3. 
Stroke and co-workers (Stroke, Cole, Simhadri, Brescia, Desai, Zhang et al., 2006) 
previously reported the identification of two small-molecule agonists of CXCR3; named 
compound #1 (Cp#1) and compound #3 (Cp#3).  Both small- molecules share a similar 
chemical structure consisting of an N-containing bicyclic unit, a hydrophobic group and a 
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basic amino acid (Fig.1A).  In the first instance we assessed the agonistic activities of Cp#1 
and Cp#3, in chemotactic assays using the human lymphoblast line H9 (which expresses 
endogenous CXCR3) and previously described murine L1.2 wild type (WT) CXCR3-
transfectants (Xanthou, Williams & Pease, 2003).  Both compounds induced typically bell-
shaped chemotactic responses from either cell line, with 100nM-1µM of either small- 
molecule inducing an optimal response.  Both Cp#1 and Cp#3 were partial agonists compared 
to the natural ligands CXCL11 and CXCL10, which exhibited more potent and efficacious 
responses as previously reported (Stroke, Cole, Simhadri, Brescia, Desai, Zhang et al., 2006) 
(Fig. 1B, C).  Notably, Cp#1 and Cp#3 were an order of magnitude more potent at H9 cells 
c.f. CXCR3 transfectants which may reflect their ability to induce  more efficient coupling of 
CXCR3 to  human G proteins or that CXCR3 expression levels were higher in this cell line.   
 
Disparate binding sites on CXCR3 for CXCL10 and CXCL11  
Previous studies have described CXCL10 and CXCL11 as allosteric ligands of CXCR3, 
based on their respective abilities in heterologous competition binding assays.  Whilst 
CXCL11 is reported to completely displace CXCL10 from the receptor, the reciprocal is not 
apparent, with a considerable proportion of bound CXCL11 unable to be displaced by 
CXCL10 (Cox, Jenh, Gonsiorek, Fine, Narula, Zavodny et al., 2001; Xanthou, Williams & 
Pease, 2003).    To examine the activity of the compounds further we subjected L1.2 
transfectants expressing WT CXCR3 to heterologous competition assays using 125I-CXCL10 
and 125I-CXCL11 (Figure 2A and B).  Radiolabelled CXCL10 was readily displaced from 
cells by CXCL11, CXCL10 and Cp#3, (Respective IC50 values of 0.4nM, 2.0nM and 3.0 nM) 
whilst Cp#1 was unable to compete more that 25% of the radiolabel.  125I-CXCL11 was 
readily displaced by unlabelled CXCL11 (IC50 values of 1.2nM) but was resistant to 
increasing concentrations of either CXCL10 or the two small molecule agonists, which were 
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unable to displace more than 50% of the 125I-CXCL11.  This suggests that Cp#1 and Cp#3 
mimic CXCL10 with respect to ligand binding and that CXCL10 and CXCL11 are allosteric 
ligands of CXCR3.    
 
The second extracellular loop of CXCR3 is critical for agonist function 
Previous work by ourselves using chimeric CXCR1/CXCR3 receptors suggested a multi-site 
model for the interaction of CXCR3 with its ligands in which multiple extracellular domains 
are required for  chemokine binding and receptor activation, notably the second and third 
extracellular loops (ECLs) of CXCR3 (Xanthou, Williams & Pease, 2003).  To assess 
whether the small-molecule agonists activated CXCR3 in a similar fashion, we used two 
chimeric constructs from our previous study where the second and third ECLs of CXCR3 
were exchanged with the corresponding regions of CXCR1 to generate the constructs Chi-7 
and Chi-8 respectively (Fig. 3A).  Both ECL2 and ECL3 share limited sequence homology 
(16% and  23% identity respectively).  Both Chi-7 and Chi-8 were transiently expressed as 
detected by flow cytometry (data not shown).  The chemotactic responses of the L1.2 
transfectants to increasing concentrations of Cp#1 and Cp#3 were compared to that of WT-
CXCR3.  Replacement of ECL2 of CXCR3 with that of CXCR1 (Chi-7) resulted in a loss of 
chemotactic responses to both Cp#1 and Cp#3 (Fig. 3B, 3C), whilst the replacement of ECL3 
(Chi-8) markedly reduced the efficacy of the chemotactic responses compared to WT-
CXCR3 transfectants but did not ablate them.  Thus, as is the case for the natural agonists, 
ECL2 and ECL3 of CXCR3 appear important for functional responses to synthetic agonists.  
 
Small-molecule agonists of CXCR3 appear to mimic a portion of the 30’s loop of the 
natural ligand CXCL10. 
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We subsequently compared the structure of Cp#1 and Cp#3 with the natural CXCR3 agonists 
CXCL10 and CXCL11. As the tetrahydroisoquinoline ring in Cp#1 imposes conformational 
restraints similar to proline residues in peptide chains, the amino acid sequences of CXCR3 
ligands were searched for candidate sequences containing a Pro-Arg-X or Pro-Lys-X motif 
(X corresponding to a hydrophobic residue). One such five-residue sequence of CXCL10 
spanning amino acids 35-39 of CXCL10 (Phe-Cys-Pro-Arg-Val) matched these requirements, 
and the coordinates for these atoms were taken from the previously solved NMR structure of 
CXCL10 (Booth, Keizer, Kamphuis, Clark-Lewis & Sykes, 2002). Keeping the atomic 
coordinates of the CXCL10 atoms fixed, there was an attempt to align both compounds to the 
peptide sequence of CXCL10 but only Cp#1 was successfully aligned (Fig. 4A) , revealing 
obvious structural similarities with the 30’s loop region of CXCL10 which connects the first 
two strands of the anti-parallel β-pleated sheet. (Fig. 4B).  
 
 
 
Biological responses to CXCL10 but not CXCL11 are susceptible to mutation of acidic 
residues in the second transmembrane helix and the second extracellular loop 
 
Examination of the CXCR3 primary sequence highlighted 7 acidic residues within CXCR3 
which we postulated might act as counter-ions to the basic moieties of Cp#1 and Cp#3 (Fig. 
4C).  To test this hypothesis, point mutagenesis of these acidic residues was undertaken, 
generating a panel of 7 mutant cDNA constructs in which each acidic residue (aspartate or 
glutamate) was mutated to its amide counterpart (asparagine or glutamine).  Transient 
transfection of all seven constructs suggested that they were expressed at levels not 
significantly different from that of WT CXCR3 (Fig. 5A, Table 1).  The same transfectants 
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were initially subjected to homologous competition radiolabelled binding, using either 0.1nM 
125I-CXCL11 (Fig. 5B) or 0.1nM 125I-CXCL10 (Fig. 5C) and a single 1000-fold excess of 
cold ligand.  125I-CXCL11 binding was robust amongst all mutants, with the exception that 
the D112N mutant bound 125I-CXCL11 at detectable but significantly reduced levels (Fig. 
4B) compared to WT CXCR3.  In contrast, 125I-CXCL10 binding was extremely sensitive to 
mutation, with several mutants displaying significantly reduced ligand binding, notably the 
D112N, D195N and E196Q mutants (Fig. 5C).  Homologous competition assays employing a 
series of unlabelled ligand concentrations were subsequently used to determine the relative 
affinity of each ligand for the mutants (Figures 6A & 6B and Table 1).   
 
D112, E195 and E196 of CXCR3 are specifically required for receptor activation by 
CXCL10 but not CXCL11  
We subsequently examined the activities of each CXCR3 mutant in chemotaxis assays, 
examining migratory responses to increasing amounts of CXCL11, CXCL10, Cp#1 or Cp#3 
(Fig. 7A-D).  In keeping with the 125I-CXCL11 binding data, all of the CXCR3 mutants 
migrated in a dose-dependent fashion to CXCL11 (Fig. 7A) with optimal chemotaxis for the 
majority of constructs observed at 30nM, identical to that of WT CXCR3 transfectants.  The 
CXCL11-mediated responses of D282N, E293Q and D297N were right-shifted, suggesting 
that these residues play a role in receptor activation by CXCL11.  In the case of the D297N 
construct the reduced potency of CXCL11 in chemotaxis assays correlated with a significant 
decrease in affinity for CXCR3 compared to WT CXCR3 (Kd of 10.9nM c.f. Kd of 26.3nM).  
The majority of CXCR3 mutants also responded to CXCL10 in the same manner as WT 
CXCR3, exhibiting the bell-shaped dose response curve typical of these assays, with a 
maximum response to 30nM CXCL10 (Fig. 7B).  Unlike the robust CXCL11 responses, 
chemotaxis to CXCL10 was significantly impaired for several mutants.  Notably, cells 
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expressing the D112N, D195N and E196Q were unresponsive to CXCL10. In the main, this 
correlated with a decreased ability to bind 125I-CXCL10, although for the D195N mutant the 
affinity was almost identical to that of WT CXCR3, suggesting that D195 is critical for 
receptor activation but not binding of CXCL10. As was the case for CXCL10, transfectants 
expressing the D112N, D195N and E196Q mutants were also unresponsive to Cp#1 (Fig. 7C) 
and Cp#3 (Fig. 7D), suggesting that with respect to their biological activity, the compounds 
mimic CXCL10.  
 
To assess the effects of the D112N, D195N and E196Q mutations on the ligand binding sites 
of Cp#1 and Cp#3, we examined the ability of the compounds to displace 125I-CXCL10 from 
transfectants expressing the mutant constructs, albeit with some experimental limitations.  
Firstly, 125I-CXCL11 was omitted from these experiments as we had previously shown that 
neither compound was able to effectively displace the radioligand  (Figure 2B).  Secondly, 
the D112N mutation was omitted from these experiments as this construct was unable to 
effectively bind CXCL10 (Figure 6B).  Thirdly, the significant drop in Bmax for 125I-
CXCL10 binding at the D195N and E196Q mutants coupled with the relatively poor ability 
of Cp#1 to displace 125I-CXCL10 lead us to omit Cp#1 from these experiments.  This left us 
with experimental determination of the relative Kd values for Cp#3 at cells expressing WT 
CXCR3 and the D195N and E196Q variants (Figure 7E).  Whilst the D195N mutant behaved 
essentially as WT CXCR3 in these assays (EC50 values of 3.2nM and 8.2nM respectively), 
the ability of Cp#3 to displace 125I-CXCL10 from cells expressing the E196Q mutant was 
significantly impaired, with less than 50% of the radiolabel displaced with a 3000-fold molar 
excess of Cp#3.  
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DISCUSSION AND CONCLUSIONS 
Current models of chemokine receptor activation are based predominantly on the two-step 
model of receptor activation, in which the chemokine is initially tethered by the receptor N-
terminus and orientated such that key regions of the chemokine can then make productive 
interactions with other regions of the receptor (Monteclaro & Charo, 1996; Pease, Wang, 
Ponath & Murphy, 1998).  Several studies have implicated the N-terminus and 30’s loop 
regions of chemokines as playing critical roles in receptor activation, with truncation and 
mutation of either chemokine domain typically resulting in a loss of activity (Clark-Lewis, 
Dewald, Loetscher, Moser & Baggiolini, 1994; Crump, Gong, Loetscher, Rajarathnam, 
Amara, Arenzana-Seisdedos et al., 1997; Gong & Clark-Lewis, 1995; Jarnagin, Grunberger, 
Mulkins, Wong, Hemmerich, Paavola et al., 1999).  The discovery of small-molecule 
agonists of chemokine receptors has allowed us to bypass the N-terminal tethering event and 
ask questions about which residues of the receptor are implicated in activation. We describe 
here, the characterization of two small-molecule agonists of CXCR3, Cp#1 and Cp#3, which 
activate CXCR3 by binding to an intrahelical pocket.  Such compounds are currently under 
investigation as potential therapies for transplant rejection, where the desensitisation of 
CXCR3 may be envisaged to dampen the recruitment of T-cells to the allograft (O’Boyle, 
2010) or as agents for promoting bone marrow regeneration following chemotherapy (Han, 
2010).  
In the case of Cp#1, it appears that the activity of the molecule results from its ability to 
successfully mimic the 30’s loop of the natural chemokine agonist, CXCL10.  This is 
supported by alignment of the small-molecule agonists with the solution structure of 
CXCL10, with Cp#1 mimicking the Pro-Arg-Val sequence, formed of residues 37-39 within 
the 30’s loop region of the chemokine.  Lending credence to our findings, Arg-38 is one of 
several CXCL10 residues reported to undergo a conformational change upon binding of the 
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chemokine to a peptide corresponding to the CXCR3 N-terminus (Booth, Keizer, Kamphuis, 
Clark-Lewis & Sykes, 2002).  Collectively, our data is reminiscent of studies of the urotensin 
receptor in which a peptidomimetic was generated from the Trp-7, Lys-8, and Tyr-9 triplet of 
urotensin (Flohr, Kurz, Kostenis, Brkovich, Fournier & Klabunde, 2002) and supports the 
notion that virtual screening of pharmocophores comprised of the 30’s loop region of 
chemokines could be a general strategy for the identification of compounds with agonist 
activity.  
We have identified three residues of CXCR3 which were critical for receptor activation by 
Cp#1 and Cp#3, namely D112, D195 and E196.  Of significance was our finding that 
mutation of these three acidic residues ablated responses to CXCL10 but not responses to 
CXCL11.  This suggests that D112, D195 and E196 of CXCR3 are required to bind and be 
activated by CXCL10, resulting in productive signaling as measured by chemotaxis.  In 
contrast, mutation of D112, D195 and E196 does not preclude binding and stabilization of an 
active CXCR3 conformation by CXCL11.  Interestingly, the equivalent of the Pro-Arg-Val 
sequence of the 30’s loop region of CXCL11 is Asp-Lys-Ile, suggesting that in order to 
activate CXCR3, the basic charge at this position has to be in the context of the 
conformational restraints imposed by Pro-37 in CXCL10 or the tetrahydroisoquinoline ring 
found in Cp#1. 
 
Combining our experimental data with Ab initio modelling of CXCR3 we find that D112 is 
located at the extracellular end of helix II, and acts as a counterion for the arginine moiety of 
the small-molecules (Fig. 8A & B), which mimics the interaction of R38 of the natural ligand 
CXCL10 with the receptor.   Previous mutagenesis of D112 to lysine or alanine was reported 
to result in a loss of both CXCL10 and CXCL11 binding and chemotactic responses to both 
ligands (Colvin, Campanella, Manice & Luster, 2006).  Here we show that mutation of D112 
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to asparagine, which preserves some features of the aspartate sidechain but loses the negative 
charge, results in a selective loss of CXCL10 binding and chemotactic response.  Comparison 
of the binding site of the compound called “1t” in the CXCR4 crystal structure (Wu, Chien, 
Mol, Fenalti, Liu, Katritch et al., 2010) to the predicted binding site of Cp#3 in CXCR3 
shows that the two compounds bind in similar locations in their respective receptors (Fig. 
8C). However, since Cp#3 is larger than 1t, its binding site extends more towards TM1 and 
TM7 as shown in Figure 8C.  The CXCR4 crystal structure reveals a severely tilted TM3 that 
is not observed in our model of CXCR3. The tilt accounts for the differences in the respective 
position of the ligands in our model. 
 
D195 and E196 are located within the second extracellular loop (ECL2), a region of CXCR3 
that ourselves and others have previously shown to be critical for activation of CXCR3 
(Colvin, Campanella, Manice & Luster, 2006; Xanthou, Williams & Pease, 2003).  Modelling 
of the extracellular loops (Fig. 8D) suggests that these residues form putative intermolecular 
salt bridges which stabilize CXCR3 and presumably gate entry of the ligand into the binding 
pocket as has been previously shown for the β2-adrenergic receptor (Wang & Duan, 2009).  
In our model, D195 and E196 of ECL2 form salt bridges with R288 of ECL3 and K125 of 
ECL1 respectively.  It is noteworthy that when we previously characterized the Chi-8 
construct in which ECL3 of CXCR3 was replaced by the corresponding region of CXCR1 
(Fig 3A), although CXCL11 binding was well preserved, CXCL10 binding was abolished 
(Xanthou, Williams & Pease, 2003).  With inference to our model described here, we can 
now attribute the lack of CXCL10 binding to the loss of the salt bridge between D195 and 
R288, as a glutamate residue resides in the analogous position within ECL3 of CXCR1 
(E275).   
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The contrasting binding profiles of CXCL10 and CXCL11 in heterologous competition 
assays (Fig. 2A and B) coupled with the mutagenesis of D112, D195 and E196 which ablated 
CXCL10 but not CXCL11 function, provide more detailed information regarding the 
previous observation that the two chemokines are allosteric ligands of CXCR3 (Cox, Jenh, 
Gonsiorek, Fine, Narula, Zavodny et al., 2001).  How the two ligands interact with CXCR3 is 
undoubtedly more complex than a simple allosteric mode of binding in which both 
chemokines would displace each other to a similar degree.  One possible explanation is that 
CXCL11 binds to a population of CXCR3 molecules which is inaccessible to CXCL10, 
perhaps higher order oligomers of CXCR3 or receptors pre-coupled to intracellular 
molecules.  Alternatively, CXCL10 and CXCL11 may stabilise distinct receptor 
conformations.  This raises the possibility that the two chemokines may induce ligand-
selective bias at CXCR3 (Kenakin 2011) with the different CXCR3 conformations stabilized 
by either ligand coupling to distinct intracellular signalling pathways.  In this study our 
readout of biological activity was chemotaxis, which is the final downstream function of 
CXCR3 activation and may be arrived at by several signalling pathways.  To further examine 
such possibilities, pathway-specific assays would need to utilised.   
 
Ligand binding data similar to that shown here has been published regarding the binding of 
CCL5 and CCL3 at the CC chemokine receptor, CCR1 (Jensen, Thiele, Ulven, Schwartz & 
Rosenkilde, 2008).  This raises an interesting question as to whether there is an evolutionary 
benefit to be able to activate signalling pathways via distinct chemokine receptor 
conformations.  The promiscuous nature of many chemokines (activating several different 
receptors) has led commentators to propose that the apparent redundancy in the system 
affords a host the possibility of mounting robust immune responses in the face of pressure 
from microorganisms (Mantovani, 1999).  Since pathogens are known to produce chemokine 
 - 19 - 
mimetics which can directly antagonise chemokine receptors (Damon, Murphy & Moss, 
1998; Luttichau, Stine, Boesen, Johnsen, Chantry, Gerstoft et al., 2000) it may be beneficial 
for a host to be able to activate receptors by distinct mechanisms, enhancing the prospects 
that at least one cognate ligand may signal under duress.  From a pharmacological 
perspective it raises the intriguing possibility that specific compounds could be developed 
which block the activation of an undesirable signalling pathway at a single chemokine 
receptor but leave intact the ability to activate a desirable signalling pathway.  In therapeutic 
terms, such molecules would serve to dampen down an inflammatory response without 
comprising host immunity.   
 - 20 - 
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FIGURE LEGENDS 
 
Table 1- Expression, chemotaxis and binding properties of CXCR3 mutants.  
Surface expression and chemotaxis are expressed as a comparison to values obtained for 
transfectants expressing WT CXCR3 . IC50 values are denoted in nM. ND indicates not 
determined.  The mean values ± S.E.M. from at least three experiments are shown in each 
case. ***: p<0.001, **: p<0.01 and *: p<0.05 according to Student’s t-test.  
 
Figure 1 – Basic small-molecules are partial agonists of CXCR3.   
A.  The chemical structures of compounds (Cp) # 1 & 3.  B & C. The chemotactic responses 
of the human lymphoblast cell line H9 and L1.2 CXCR3 transfectants to increasing 
concentrations of CXCL10, CXCL11, Cp# 1 and Cp# 3.   
 
Figure 2 – Small-molecule agonists of CXCR3 mimic CXCL10 in their ability to displace 
CXCR3 ligands from their receptor.  
A. & B.  The relative abilities of unlabelled CXCL10, CXCL11, Cp#1 or Cp#3 to displace 
125I-CXCL10 (A) or 125I-CXCL11 (B) from WT CXCR3 transfectants in heterologous 
competition assays.   
 
 
Figure 3 – The second extracellular loop of CXCR3 appears critical for small-molecule 
agonist function.   
 - 26 - 
A The identity of previously described CXCR3 chimeras.  B & C. The chemotactic responses 
of L1.2 transfectants expressing WT CXCR3 or chimeric constructs to increasing 
concentrations of Cp# 1 and Cp# 3.   
 
Figure 4 – Small-molecule agonists of CXCR3 appear to mimic the 30’s loop of the natural 
ligand CXCL10 .   
A.  The alignment of a five-residue sequence of CXCL10 spanning amino acids 35-39 (Phe-
Cys-Pro-Arg-Val) with Cp#1.  CXCL10 is depicted in grey and is overlaid with Cp#1 (cyan).  
B.  Modelling of the CXCL10 crystal structure, with the pertinent side chains in the 30’s loop 
highlighted.  C.  Acidic residues in CXCR3 (closed circles) mutated to their amide 
counterpart.  
 
Figure 5 – CXCL10 but not CXCL11 binding is susceptible to mutation of D112, D195 and 
E196 residues. 
A.  The relative expression profiles of mutant CXCR3 constructs compared to WT CXCR3.  
B. & C. Levels of 125I-CXCL11 (B) or 125I-CXCL10 (C) specifically bound to the mutant 
CXCR3 constructs.   
 
Figure 6 – Mutation of several acidic residues in the first and second extracellular loops of 
CXCR3 significantly increases affinity for CXCL11 but not CXCL10.  A. & B. The relative 
abilities of increasing concentrations of unlabelled ligand to displace 0.1nM 125I-CXCL11 (A) 
or 0.1nM 125I-CXCL10 (C) in homologous competition assays using CXCR3 transfectants.   
 
Figure 7 – Mutation of D112, D195 and E196 ablates chemotaxis to CXCL10 and small-
molecule CXCL10 mimetics but has little effect on CXCL11 responses.  The relative abilities 
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of CXCR3 transfectants to migrate in response to increasing concentrations of CXCL11 (A), 
CXCL10 (B), Cp#1 (C) and Cp#3 (D) in chemotaxis assays. Panel E shows the relative 
abilities of increasing concentrations of Cp#3 to displace 125I-CXCL10 from transfectants 
expressing WT CXCR3 or the mutants constructs D125N and E196Q.  
 
Figure 8 – Ab initio modelling of CXCR3  
A. & B.  Top views of a model of human CXCR3 predicted using MembStruk showing the 
small-molecule agonists compound 1 (A) and compound 3 (B) residing in a binding site 
predicted using Glide XP.  In both models, D112 acts as a counter ion for the basic moiety of 
either compound, with a predicted cluster of predominantly hydrophobic residues interacting 
with the ligand in the binding site. Numbers in parenthesis refer to the helix (1-7) in which 
the residue resides.  C.  Comparison of the binding site of the compound called “1t” in the 
CXCR4 crystal structure (pink) to the predicted binding site of Cp#3 in CXCR3 (cyan) shows 
that the two compounds bind in similar locations in their respective receptors.  D. The two 
predicted salt bridges within the extracellular domains of CXCR3 between K125 (ECL1) and 
D196 (ECL2) and between R288 (ECL3) and D195 (ECL2).   
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